Aim: To identify neonatal magnetic resonance imaging (MRI) features that predict the likelihood of children with congenital cytomegalovirus (cCMV) developing epilepsy, together with clinical features and a validated MRI scoring system.Method: This was a retrospective descriptive cohort study of infants with cCMV referred to a paediatric infectious disease centre between April 2012 and March 2022, and followed up for at least 2 years. MRI was performed before 4 months of age and assessed by two paediatric neuroradiologists.Results: Ninety children with cCMV were included, 46 were female and 44 were male. The median age at MRI was 20 days, (standard deviation = 34, range = 1–200). Seventy‐two of 90 children were symptomatic at birth and 7 of 72 developed epilepsy (9.7% of symptomatic infants, 7.8% of total). None of 18 asymptomatic children developed epilepsy. Those with epilepsy were more likely to be symptomatic at birth (100% vs. 76%, p = 0.14) and to have cortical malformations (86% vs. 15%, p < 0.001). Infants with polymicrogyria (PMG) were more likely to develop epilepsy (odds ratio = 35 [3.9–317.1], p < 0.001). A 1‐year remission was achieved in three of seven children; four required multiple antiseizure medications without remission.Interpretation: The strongest correlate of epilepsy development was PMG. Infants with symptomatic cCMV at birth and PMG were more likely to develop epilepsy, and were likely to require one or more antiseizure medications. Parents of infants with cCMV and cortical malformations should be counselled regarding this risk. Including PMG severity in cCMV MRI scoring could improve epilepsy risk prediction.
Evaluate variation in care of febrile infants presenting to London hospitals and adherence to national Clinical Practice Guidelines (CPGs). Retrospective multicentre cohort study conducted at 21 London hospitals. Infants ≤ 90 days of age presenting with fever or caregiver reported fever between 1st April 2021—31st March 2022 were included. Outcome measures were variations in patient management and adherence to national CPGs. Of 2,008 presentations, 41.1% were febrile during assessment. 73.7% had blood tests (range across hospital sites: 55.4–96.7%), 40.8% had cerebrospinal fluid (CSF) testing (17.1–70.7%), 63.4% had urinalysis (43.4–85.4%) and 62.2% were investigated for SARS-CoV2 (26.5–91.7%). Antibiotics were started in 57.7% (35.4–90.2%) and 63.5% (46.7–99.2%) were admitted. Infants aged < 28 days and infants febrile during assessment were more likely to undergo investigations and be admitted. Adherence varied significantly across sites: full adherence to CPGs was achieved in 21.9% (site range 8.8–35.4%), partial adherence in 24.4% (18.0–35.3%), non-adherence in 31.2% (10.6–47.4%), and over-adherence in 23.5% (8.0–44.7%). CPG adherence was higher in infants aged < 28 days. Conclusions : There was wide variation in care across London hospitals with limited adherence to guidelines. This highlights the need to focus on refining and updating decision models and CPGs, with more specific recommendations for managing infants who are afebrile during initial assessment. Clear guidance with a focus on reducing missed diagnosis may impact patient safety and economical expenditure. What is Known: • Febrile infants present frequently to emergency departments .• 10–20% will have a serious bacterial infection (SBI) .• Detecting those that need timely investigations, antimicrobial treatment and hospital admission can be challenging . What is New: • This large multicentre study shows wide variation in management across London hospitals .• It demonstrates that full adherence to national guidelines is achieved in fewer than a quarter of infants .• Adherence is lower in older infants and infants who are febrile at home but afebrile during assessment .
The prevalence of invasive bacterial infection in young febrile infants is estimated at 1%–4%, with the highest rates in those <21 days.1 UK guidelines recommend screening all febrile neonates for bacterial infection and starting empiric broad-spectrum antibiotics while awaiting results,2–4 but not routine antiviral therapy. However, a recent UK/Ireland prospective surveillance study reported an increased incidence of neonatal herpes simplex virus (HSV) infection of 6.0 per 100 000 live births, with substantial associated morbidity and mortality.5